You haven't searched anything yet.
At 4D Molecular Therapeutics, Inc. (“4DMT”), we boldly innovate to unlock the full potential of genetic medicines for countless patients. We are committed to breaking boundaries and daring to cure as we develop new and foundational products and product components through our growing technology platforms.
4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution (TVE), which combines the power of directed evolution with our approximately one billion synthetic AAV capsid-derived sequences to invent evolved vectors for use in our products. We believe key features of our targeted and evolved vectors will help us create targeted product candidates with improved therapeutic profiles. These profiles will allow us to treat a broad range of large market diseases, unlike most current genetic medicines that generally focus on rare or small market diseases.
We have built a deep portfolio of AVV-based gene therapy product candidates, with five product candidates in clinical trials: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease, 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, we have two product candidates in preclinical studies: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency.
To-date, we have demonstrated clinical proof-of-concept for three evolved vectors in three therapeutic areas and routes of administration with five products and patient populations. We believe this validates the power of our directed evolution platform for discovering superior vectors compared to wildtype viral vectors. We have built a robust and efficient product engine with 6 open Investigational New Drug Applications (INDs) in the U.S., 1 IND in Taiwan, and 1 Clinical Trial Approval (CTA) in Australia. We believe we are positioned to create, develop, manufacture and, if approved, effectively commercialize targeted genetic medicines that could transform the lives of patients suffering from debilitating diseases.
In addition to TVE, our technology includes a robust AAV manufacturing platform and onsite manufacturing facility that allows us to rapidly produce and test research grade material and scale up to GMP clinical material. This internal capability and close collaboration between our R&D and Manufacturing teams has greatly accelerated the pace of discovery at 4DMT.
Company Differentiators:
GENERALSUMMARY:
As a genetic medicines platform company, 4DMT operates in a crowded and complex competitive environment. Understanding the unmet medical needs in our therapeutic areas of interest and closely tracking competitor advancements is essential to making strategic development and partnership decisions. To support these key activities, the Director reports to the Vice President of Portfolio & Product Strategy, focusing on strategic analyses that support the company’s portfolio planning prioritization and product development. This position interfaces with various members of other teams across the company including Clinical Science, Clinical Operations, Translational Medicine, Project Management, Discovery and Engineering, Finance.
RESPONSIBILITIES:
EXPERIENCE:
Required:
Skills:
Base salary compensation range:
Minimum:
Maximum:
Bay Area Range
$214,000
$255,000
Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.
Full Time
Scientific Services
$209k-250k (estimate)
08/13/2023
05/04/2024
4dmoleculartherapeutics.com
EMERYVILLE, CA
50 - 100
2013
Public
DAVID KIRN
$10M - $50M
Scientific Services
4DMT is a biotechnology company that researches, develops and commercializes gene therapeutics for the treatment of cancer.